


Supplementary Figure 10



Supplementary Figure 10 (related to Figure 7). Impairment of CSC agrin is sufficient to impair PDAC growth in an orthotopic cell line model. (A) Experimental layout (related to figure 7A): to impair agrin expression in specific cancer cell subpopulations, CSC and NSCC were sorted from the MIA PaCa-2 Tet-Off shAgrin/shScramble clones, and then orthotopically implanted into the pancreas of Rag2^{-/-}Il2rg^{-/-} mice. In this case, both groups are treated with doxycycline, therefore both groups express normal levels of Agrin. **(B)** Tumor growth curve measured by ultrasound of doxycycline treated CSC from MIA PaCa-2 Tet-Off shAgrin with NSCC from MIA PaCa-2 Tet-Off shScramble tumors (injected at the same percentages found in the cells of origin; n=7), and doxycycline treated NSCC from MIA PaCa-2 Tet-Off shAgrin with CSC from MIA PaCa-2 Tet-Off shScramble tumors (injected at the same percentages found in the cells of origin; n=6; two-way anova). **(C)** Quantification of tumor growth using the last ultrasound measurement of pancreas tumors in doxycycline treated (WT) or untreated (KD) CSC from MIA PaCa-2 Tet-Off shAgrin with NSCC from MIA PaCa-2 Tet-Off shScramble group and doxycycline treated (WT) or untreated (KD) NSCC from MIA PaCa-2 Tet-Off shAgrin with CSC from MIA PaCa-2 Tet-Off shScramble group (left to right, paired t-test, * $p < 0.05$). **(D)** Schematic representation of Agrin allele recombination and representative photo of an agarose gel with the results of a PCR of Agrin^{fl/fl} allele recombination in pancreatic tumors of KPC and KPAC. **(E)** Representative photos of the colorimetric assay (left) and representative brightfield photos (right) of PDX cells treated ex vivo with anti-agrin blocking antibody (Mab5204 10 μ g/mL), IgG (10 μ g/mL) or untreated.